DDInter1718 DDInter1376
Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Sufentanil {u} (Compound) resembles {v} (Compound) Anileridine
Sufentanil {u} (Compound) binds {v} (Gene) OPRM1
Sufentanil {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Sufentanil {u} (Compound) causes {v} (Side Effect) Vomiting
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desmopressin
Sufentanil {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Sufentanil {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Sufentanil (Compound) resembles Anileridine (Compound)
Sufentanil (Compound) binds OPRM1 (Gene)
Sufentanil (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Sufentanil (Compound) causes Vomiting (Side Effect)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin
Sufentanil may lead to a major life threatening interaction when taken with Dexfenfluramine
Sufentanil may lead to a major life threatening interaction when taken with Naltrexone